In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), with a price target of $32.00. The company’s shares closed last Friday at $15.97.
Matteis covers the Healthcare sector, focusing on stocks such as Neurogene, Dyne Therapeutics, and ACADIA Pharmaceuticals. According to TipRanks, Matteis has an average return of 6.8% and a 45.31% success rate on recommended stocks.
Currently, the analyst consensus on Alto Neuroscience, Inc. is a Strong Buy with an average price target of $32.33.
The company has a one-year high of $24.00 and a one-year low of $12.83. Currently, Alto Neuroscience, Inc. has an average volume of 364.2K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANRO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alto Neuroscience, Inc. (ANRO) Company Description:
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients¿ brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.
